The Manila Times

TREMFYA® (guselkumab) receives European Commission approval for subcutaneous induction through to maintenance in adults with ulcerative colitis, now the first IL-23 inhibitor ...

Guselkumab offers the flexibility of self-administration from the start of treatment in both ulcerative colitis (UC) and Crohn’s disease (CD),1,2,3 providing the simplicity of a fully subcutaneous ...
The Pharma Letter

New EC approval for J&J’s Tremfya scores a first

US healthcare giant Johnson & Johnson today announced that the European Commission (EC) has approved the expansion for the ...
FiercePharma

J&J lands Tremfya one-two punch in IBD with first ulcerative colitis win and long-term Crohn's data

Janssen has debuted the first safety and efficacy data on Tremfya in ulcerative colitis, and so far, prospects for a label expansion look good. The readout accompanies positive 48-week results in ...
Healio

Tremfya nabs FDA approval for active ulcerative colitis, chasing competitor Skyrizi

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Johnson & Johnson’s Tremfya, a dual acting interleukin-23 inhibitor, for the treatment of ...
Morningstar

New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis

Improvement in both joint and skin symptoms reinforce TREMFYA® as a first-line treatment option with a proven safety profile for adults with active psoriatic arthritis BARCELONA, June 11, 2025 ...
Morningstar

TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years

Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 92 SAN DIEGO, Calif., ...
WebMD

Managing Ulcerative Colitis With Tremfya

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...
MM&M

Boosted by March Madness, Tremfya takes the lead in TV pharma ad rankings

Psoriasis drugs dominated the TV pharma ad landscape in March, as Johnson & Johnson’s Tremfya and AbbVie’s Skyrizi secured the top two spots in iSpot.tv’s ad rankings. The two drugs rose up the list ...
MM&M

Tremfya takes top pharma TV ad impressions title from Dupixent for June

Tremfya snagged Dupixent’s place as the pharma brand with the most TV impressions in June, according to data released by iSpot.tv on Friday morning. The Johnson & Johnson brand garnered a 4.3% share ...
Healio

FDA approves Tremfya for pediatric plaque psoriasis, active psoriatic arthritis

Please provide your email address to receive an email when new articles are posted on . The FDA expanded the indication for Tremfya (guselkumab) to children with plaque psoriasis or active psoriatic ...
Healthline

Side Effects of Tremfya: What You Need to Know

Mild side effects of Tremfya include injection site reactions and upper respiratory infections. Though rare, Tremfya can also cause serious side effects, including severe infections. Your doctor may ...
WebMD

Managing Psoriatic Arthritis With Tremfya

People with psoriatic arthritis (PsA) often take medicines to help manage their condition and improve their symptoms. Some of these medicines work directly on the body's immune system and help to ...